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Amiodarone inhibits arterial thrombus formation and tissue
factor translation
Abstract
BACKGROUND: In patients with coronary artery disease and reduced ejection fraction, amiodarone
reduces mortality by decreasing sudden death. Because the latter may be triggered by coronary artery
thrombosis as much as ventricular arrhythmias, amiodarone might interfere with tissue factor (TF)
expression and thrombus formation. METHODS AND RESULTS: Clinically relevant plasma
concentrations of amiodarone reduced TF activity and impaired carotid artery thrombus formation in a
mouse photochemical injury model in vivo. PTT, aPTT, and tail bleeding time were not affected;
platelet number was slightly decreased. In human endothelial and vascular smooth muscle cells,
amiodarone inhibited tumor necrosis factor (TNF)-alpha and thrombin-induced TF expression as well as
surface activity. Amiodarone lacking iodine and the main metabolite of amiodarone,
N-monodesethylamiodarone, inhibited TF expression. Amiodarone did not affect mitogen-activated
protein kinase activation, TF mRNA expression, and TF protein degradation. Metabolic labeling
confirmed that amiodarone inhibited TF protein translation. CONCLUSIONS: Amiodarone impairs
thrombus formation in vivo; in line with this, it inhibits TF protein expression and surface activity in
human vascular cells. These pleiotropic actions occur within the range of amiodarone concentrations
measured in patients, and thus may account at least in part for its beneficial effects in patients with
coronary artery disease.
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Amiodarone Inhibits Arterial Thrombus Formation and
Tissue Factor Translation
A. Breitenstein, S.F. Sta¨mpfli, G.G. Camici, A. Akhmedov, H.R. Ha, F. Follath, A. Bogdanova,
T.F. Lu¨scher, F.C. Tanner
Background—In patients with coronary artery disease and reduced ejection fraction, amiodarone reduces mortality by
decreasing sudden death. Because the latter may be triggered by coronary artery thrombosis as much as ventricular
arrhythmias, amiodarone might interfere with tissue factor (TF) expression and thrombus formation.
Methods and Results—Clinically relevant plasma concentrations of amiodarone reduced TF activity and impaired
carotid artery thrombus formation in a mouse photochemical injury model in vivo. PTT, aPTT, and tail bleeding
time were not affected; platelet number was slightly decreased. In human endothelial and vascular smooth muscle
cells, amiodarone inhibited tumor necrosis factor (TNF)- and thrombin-induced TF expression as well as surface
activity. Amiodarone lacking iodine and the main metabolite of amiodarone, N-monodesethylamiodarone,
inhibited TF expression. Amiodarone did not affect mitogen-activated protein kinase activation, TF mRNA
expression, and TF protein degradation. Metabolic labeling confirmed that amiodarone inhibited TF protein
translation.
Conclusions—Amiodarone impairs thrombus formation in vivo; in line with this, it inhibits TF protein expression and
surface activity in human vascular cells. These pleiotropic actions occur within the range of amiodarone concentrations
measured in patients, and thus may account at least in part for its beneficial effects in patients with coronary artery
disease. (Arterioscler Thromb Vasc Biol. 2008;28:2231-2238.)
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Sudden cardiac death (SCD) is defined as an unexpectedfatal event occurring within 1 hour after the onset of
symptoms in an apparently healthy subject or patients with an
underlying cardiac disease not severe enough to predict such
a fatal outcome.1 About 400 000 SCD occur every year in the
United States,2 more than 75% in patients with coronary
artery disease.3–5 The most common pattern leading to SCD is
acute arterial thrombus formation initiating fatal ventricular
arrhythmias3; indeed, in several postmortem studies, acute
thrombosis was identified in the majority of coronary arteries
examined.6–8
Tissue factor (TF), as the main initiator of the coagulation
cascade, is essential for arterial thrombus formation.9 TF
expression in endothelial cells is induced by different inflam-
matory mediators including tumor necrosis factor (TNF)-,10
interleukin (IL)-1,11 or histamine,12 and, consistent with
these observations, TF expression is upregulated in athero-
sclerotic plaques of patients with unstable angina and myo-
cardial infarction.13
Amiodarone [2-butyl-3-(3,5-diiodo-4-diethylaminoethoxy-
benzoyl)-benzofuran] is widely used for the treatment of
atrial and ventricular arrhythmia,14 –16 even though it was
originally introduced as a potent coronary vasodilator.17,18
Belonging to class III antiarrhythmic drugs,19 amiodarone
is a potassium channel inhibitor in cardiac myocytes and is
known, despite its clinical effectiveness, for its low proar-
rhythmic potential. In a large meta-analysis of 13 random-
ized trials of prophylactic amiodarone treatment in patients
with symptomatic compensated congestive heart failure
(ejection fraction 40%) or after acute myocardial infarc-
tion (with variable ejection fraction), amiodarone reduced
overall rates of SCD by 29% resulting in a 13% reduction
in total mortality.20 To date it is not known whether the
beneficial effects attributed to amiodarone are solely attributable
to its electrophysiological properties or whether other mecha-
nisms, such as inhibition of arterial thrombus formation, might
be involved as well. This study was therefore designed to
investigate the effect of amiodarone on thrombus formation and
TF, the key initiator of the coagulation cascade.
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Materials and Methods
For the detailed Materials and Methods please see the supplemental
Materials and Methods (available online at http://atvb.ahajournals.
org). Briefly, C57Bl/6 mice were treated with amiodarone (80 mg/kg
with an intraperitoneal injection every 24 hours for 7 days) or vehicle
(1.43% Tween 80, 0.29% benzyl alcohol), respectively. The photo-
chemical injury model was performed 24 hours after the last
application as described previously.21 The concentration of amiod-
arone and MDEA was measured in mouse plasma and aorta by
high-performance liquid chromatography (HPLC). PTT, aPTT, tail
bleeding time, and platelet number were determined to investigate
systemic coagulation parameters.
Human aortic endothelial cells (HAECs; Clonetics, Allschwil,
Switzerland) and human aortic vascular smooth muscle cells
(HAVSMCs; Clonetics) were cultured as described.22 Protein ex-
pression was determined by Western blot analysis, and RNA by
real-time polymerase chain reaction (PCR) after isolation with
TRIzol Reagent (Invitrogen). Further, TF activity was measured with
a colorimetric assay (American Diagnostica).
Results
Amiodarone Inhibits TF Activity and Arterial
Thrombosis In Vivo at Clinically Relevant Plasma
and Tissue Concentrations
Mice were treated with amiodarone (80 mg/kg body weight,
intraperitoneal injection) or vehicle every 24 hours for 7 days.
Amiodarone and MDEA concentrations were determined in
mouse plasma as well as in thoracic aorta. Amiodarone
plasma concentration was 1.530.17 mol/L (1.050.12
mg/L), and tissue levels reached a concentration of
64.087.59 mol/g (43.695.18 g/g) (n4; Figure 1A
and 1B). MDEA levels were lower in both plasma
(0.340.08 mol/L [0.240.05 mg/L]) and tissue
(3.530.05 mol/g [2.310.33 g/g] n4; Figure 1A and
1B). Vehicle-treated mice developed carotid artery thrombo-
sis within a mean occlusion time of 39.63.0 minutes,
whereas amiodarone-treated mice occluded within a mean
time period of 83.312.1 minute (n7; P0.005; Figure
1C). Initial blood flow in carotid artery did not differ between
vehicle- and amiodarone-treated mice (0.720.06 versus
0.850.01 mL/min; n7; PNS). In contrast to the 7-day
treatment, a single bolus treatment with amiodarone did not
affect arterial thrombus formation (31.42.7 minutes [con-
trol] versus 25.11.3 minutes [amiodarone]; n5; PNS).
The 7-day amiodarone treatment impaired TF activity in
mouse carotid artery in vivo (n5; P0.05; Figure 1D). PTT
and aPTT remained unaltered (PTT: 11.500.11 seconds
[control] versus 11.190.15 seconds [amiodarone]; PNS;
n7; supplemental Table I; aPTT: 20.240.79 seconds
[control] versus 20.700.83 seconds [amiodarone]; PNS;
n7; supplemental Table I). Total platelet number was
decreased by 25% (105622103/L [control) versus
78942103/L [amiodarone); P0.05; n7; Table I),
while total leukocyte number was not affected (3.42
0.32103/L [control] versus 3.450.60103/L [amiod-
arone]; n7; PNS). Tail bleeding time remained un-
changed (393.0145.0 seconds [control] versus 349.392.3
seconds [amiodarone]; n7; PNS; supplemental Table I).
Amiodarone Inhibits TF Protein Expression and
Surface Activity
HAECs were stimulated with TNF- (5 ng/mL) or thrombin
(1 U/mL) for 5 hours in the presence or absence of amiod-
arone. Amiodarone inhibited TNF- and thrombin-induced
TF protein expression in a concentration-dependent manner;
a significant effect was observed at 3 mol/L, whereas the
maximal effect occurred at 10 mol/L and reached more than
80% inhibition (TNF-: n4; P0.001; Figure 2A; throm-
bin: n4; P0.05; Figure 2B). Amiodarone blunted TNF-–
induced TF protein expression throughout the time course
from 1 to 5 hours after stimulation (n4; P0.01; Figure
2C), and, consistent with its effect on TF expression, im-
paired TF surface activity (n4; P0.02; Figure 2D). Ami-
odarone also inhibited TF protein expression in HAVSMCs
(n6; P0.005; Figure 2E). In contrast, amiodarone did not
induce any changes in cell morphology, and no signs of
toxicity were detected by LDH release for all concentrations
applied (n4; PNS; data not shown).
MDEA and AMWI Inhibit TF Protein Expression
MDEA, the major metabolite of amiodarone in vivo,23 inhib-
ited TF protein expression in TNF-–stimulated HAECs at
3 mol/L (n4; P0.02; Figure 3A), whereas it was toxic at
higher concentrations as determined by LDH release (n4;
P0.001; data not shown). AMWI suppressed TF protein
expression to a similar extent as amiodarone (n5; P0.05;
Figure 3B). No cell damage was detected by LDH release for
all concentrations of AMWI (n5; PNS; data not shown).
Figure 1. Amiodarone inhibits TF activity and thrombosis in vivo
at clinically relevant plasma and tissue concentrations. A, Ami-
odarone concentration in mouse plasma is similar to levels
observed in humans. B, Amiodarone and MDEA accumulate in
mouse aortic vessel wall. C, Time to thrombotic occlusion after
mouse carotid artery photochemical injury in vivo. Amiodarone
impairs thrombus formation (*P0.005 vs vehicle). D, Amiod-
arone inhibits TF activity in mouse carotid artery in vivo. Values
are indicated as absorbance at 405 nm (*P0.05 vs vehicle).
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Figure 2. Amiodarone inhibits TF protein expression and surface activity. A, Amiodarone inhibits TNF-–induced TF protein expression
in human endothelial cells (*P0.001 vs TNF- alone). B, Amiodarone inhibits thrombin-induced TF protein expression (*P0.05 vs
thrombin alone). C, Amiodarone inhibits TNF-–induced TF protein expression throughout the time course of stimulation (*P0.01 vs
TNF- alone for 3, 4, and 5 hours). D, Amiodarone inhibits TNF-–induced TF surface activity (*P0.02 vs TNF- alone). E, Amiodarone
inhibits TNF-–induced TF protein expression in human vascular smooth muscle cells (*P0.005 vs TNF- alone).
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Amiodarone Does Not Affect TFPI
Neither basal nor TNF-–induced TFPI protein expression
was affected by amiodarone (n4; PNS; Figure 3C).
Amiodarone Does Not Affect TF
mRNA Expression
Real-time PCR revealed that TNF- (5 ng/mL) induced TF
mRNA expression within 1 hour (n5; P0.01; Figure 4A).
Amiodarone (10 mol/L) did not affect TF mRNA expres-
sion (n5; PNS for each time point; Figure 4A).
Amiodarone Does Not Affect Activation of MAP
Kinases and NFB
TNF- (5 ng/mL) induced a transient phosphorylation of the
MAP kinases p38, extracellular signal regulated kinase
Figure 3. N-monodesethylamiodarone (MDEA) and amiodarone lack-
ing iodine (AMWI) inhibit TF protein expression, whereas TFPI expres-
sion is unaltered by amiodarone. A, N-monodesethylamiodarone
(3 mol/L) inhibits TNF-–induced TF protein expression in human
endothelial cells (*P0.02 vs TNF- alone), whereas a concentration
of 10 mol/L is cytotoxic. B, Amiodarone lacking iodine inhibits TNF-
–induced TF protein expression (*P0.05 vs TNF- alone). C, Ami-
odarone does not affect TFPI protein (PNS vs control or TNF-).
Figure 4. Amiodarone does not affect TF mRNA expression,
MAP kinases, and NFB. A, Real-time PCR reveals that amiod-
arone does not impair TNF-–induced TF mRNA expression
(*P0.01 vs TNF- alone). Values are normalized to L28 expres-
sion. B, TNF- induces a transient phosphorylation of the MAP
kinases p38, JNK, and ERK as well as a degradation of IB-.
Amiodarone neither affect phosphorylation (PNS versus TNF-
alone for each time point) nor IB- degradation (PNS vs
TNF- alone for each time point).
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(ERK), and JNK, with a maximal effect after 15 minutes of
stimulation. Amiodarone did not alter MAP kinase activation
(n3; PNS for each time point; Figure 4B). Similarly,
activation of NFB, as determined by degradation of its
inhibitor IB-, was not affected (n3; PNS for each time
point; Figure 4B).
Amiodarone Inhibits TF Protein Translation
The effect of amiodarone on TF protein translation was
assessed by a metabolic pulse labeling experiment using
[35S]-methionine/cysteine as radioactive tracer. Amiodarone
(10 mol/L) impaired TF protein synthesis as demonstrated
by a diminished incorporation of methionine/cysteine into the
immunoprecipitated protein (n4; P0.01 versus TNF-
alone; Figure 5A). Unspecific binding of the immunoprecipi-
tating antihuman TF antibody could be excluded using
nonimmune IgG (Figure 5A).
Because potassium is essential for protein synthesis24 and
ouabain, a known Na/K-ATPase inhibitor, impairs TF
protein translation in HAECs by lowering the intracellular
potassium concentration,25 amiodarone may influence TF
expression by a similar mechanism. Intracellular K-
concentration under control conditions was 0.70.07 mol/mg
protein (n4). Ouabain (1 mol/L) decreased the K-
concentration by 60% (0.270.03 mol/mg; n4; P0.005
versus control), while amiodarone (10 mol/L) did not affect
intracellular K-concentration (0.70.05 mol/mg protein;
n4; PNS).
Amiodarone Does Not Promote TF
Protein Degradation
HAECs were stimulated with TNF- (5 ng/mL) for 3 hours
before addition of cycloheximide (5 ng/mL), amiodarone
(10 mol/L), or both. TF protein expression remained
stable under control conditions from 3 to 7 hours after
stimulation (n4; PNS versus TNF- for each time
point; Figure 5B). Cycloheximide alone did not alter TF
protein degradation (n4; PNS versus TNF- for each
time point; Figure 5B). Similarly, amiodarone did not
affect TF protein degradation, neither alone (n4; PNS
versus TNF- for each time point; Figure 5B) nor together
with cycloheximide (n4; PNS versus TNF- for each
time point; Figure 5B).
Discussion
This study shows that amiodarone, at clinically relevant
concentrations, impairs thrombus formation, arterial TF ac-
tivity, and total platelet number in vivo. Further, it demon-
strates that amiodarone reduces TF surface activity and
protein expression in human vascular cells by an inhibition of
TF translation. These results reveal a novel antithrombotic
pleiotropic action of amiodarone.
Patients receiving long-term amiodarone treatment (200
mg orally per day) exhibit plasma concentrations of
amiodarone and MDEA averaging 1.700.63 mol/L
(1.160.43 mg/L) and 1.480.53 mol/L (0.970.35
mg/L), respectively.23,26 Higher levels are observed with a
dose of 600 mg per day averaging 5.082.20 mol/L
(3.461.5 mg/L) for amiodarone and 4.261.78 mol/L
(2.791.17 mg/L) for MDEA.26,27 After intravenous ap-
plication of amiodarone, concentrations as high as
11.74 mol/L (8 mg/L) are observed.28 Because of their
lipophilic properties, both amiodarone and MDEA accu-
mulate to high concentrations in various tissues;26,27,29
indeed, in human myocardium, amiodarone and MDEA
levels reach 12.3 to 22.9 mol/g (8.4 to 15.6 g/g), and
42.3 to 78.0 mol/g (27.7 to 51.1 g/g), respectively, and
10 times higher concentrations were measured in epicar-
dial fat tissue (153.75 mol/g [105.0 g/g]).27 Mice for the
in vivo experiments were treated with amiodarone for 7
days to reach steady-state plasma and tissue levels of
the drug. Mouse amiodarone plasma concentrations
Figure 5. Amiodarone impairs TF translation, but does not affect
TF protein degradation. A, Amiodarone inhibits TF protein translation
as determined by metabolic labeling with [35S]-methionine/cysteine
(*P0.01 vs TNF- alone). B, TNF-–induced TF protein expression
is constant from 3 to 7 hours after stimulation (PNS vs 3 hours).
Cycloheximide (5 ng/mL), amiodarone (10 mol/L) alone, or amiod-
arone together with cycloheximide do not promote TF protein degra-
dation (PNS vs TNF- alone for each time point).
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(1.530.17 mol/L [1.050.12 g/mL]) as well as in the
aortic vessel wall (64.087.59 mol/g [43.695.18 g/g])
equal plasma and tissue levels in humans under chronic
amiodarone therapy. Nevertheless, mouse plasma and
tissue concentrations of MDEA were lower than those of
amiodarone, which is in contrast to findings in humans,
where comparable or even higher MDEA levels are ob-
served.23,26 This observation is in line with previous
studies and may be attributable to a different liver metab-
olism in the two species.30,31 Further, the amiodarone and
MDEA concentrations applied in our in vitro study (1 to
10 mol/L) are within a clinically relevant range. Hence,
the herein observed antithrombotic action of amiodarone
may well represent an additional mechanism by which
amiodarone reduces SCD.
TF is the key initiator of coagulation and therefore is an
essential trigger for thrombosis.32,33 In fact, reducing TF
expression impairs thrombus formation in vivo, thus un-
derscoring this concept.9 Plaque rupture, a frequent initial
event in acute coronary syndromes, leads to the exposure
of TF to the circulation resulting in acute thrombus
formation. In addition, prothrombin is expressed by vas-
cular smooth muscle cells34 and exposed to the circulating
blood under these conditions; once activated in response to
TF-induced coagulation this vessel wall– derived pro-
thrombin may well contribute to thrombus formation,
underlying the central role of TF. To investigate arterial
thrombosis in vivo, a photochemical vascular injury model
was used as it is an established method to study TF-
dependent thrombus formation.9 Mean occlusion time in
amiodarone-treated mice was more than doubled, indicat-
ing that clinically relevant concentrations of amiodarone
do indeed inhibit arterial thrombus formation in vivo. The
reduced TF activity in mouse carotid artery indicates that
amiodarone negatively regulates thrombus formation at
least in part by inhibiting TF in vivo. Amiodarone is
known to be a potent vasodilatator in veins and arteries. A
contribution of such an acute effect to the increase in mean
occlusion time can be excluded, because arterial thrombus
formation after a bolus treatment with amiodarone did not
reveal any difference as compared to the control group.
Moreover, an involvement of the extrinsic and intrinsic
pathway of the coagulation cascade could be ruled out as
PTT and aPTT were not affected by amiodarone. Never-
theless, the reduced total platelet count suggests that
platelets may contribute to the amiodarone-mediated anti-
thrombotic effect.
To assess the relevance of the amiodarone effect in human
cells, we treated human primary vascular cells with clinically
relevant amiodarone concentrations. Indeed, amiodarone ex-
hibited a consistent effect on TF activity as well as protein
expression; furthermore, the unaltered expression of TFPI
excludes a compensating effect of the impaired TF expression
and therefore underlies the possibility of a potent antithrom-
botic property of amiodarone in humans, because the balance
with TFPI, the physiological antagonist of TF, is critical for
thrombus formation.35
Amiodarone regulated TF protein expression at the
translational level, because MAP kinase activation, TF
mRNA expression, and TF protein degradation remained
unaffected. This was confirmed by a metabolic pulse
labeling experiment using [35S]-methionine/cysteine as
radioactive tracer. Besides its known antiarrhythmic prop-
erties, pleiotropic alterations of protein expression by
amiodarone have been reported.36 –38 A recent report de-
scribed decreased expression of CACNA1C, the -1C
subunit of the L-Type calcium channel, at the posttranscrip-
tional or translational level.39 Amiodarone also interferes with
mitochondrial metabolism and energy supply;40,41 a similar
mechanism could explain the impaired TF expression in
endothelial cells, because protein translation is energy depen-
dent. Ouabain, an established Na/K-ATPase inhibitor, is
known to deplete intracellular potassium concentration in
endothelial cells and in turn downregulates TF protein ex-
pression at the translational level.24,25 Such an effect can be
excluded for amiodarone, because it does not affect intracel-
lular potassium levels.
Dealkylation is the first step in degradation of amiod-
arone and results in the pharmacologically active metabo-
lite MDEA which exhibits plasma levels comparable to
amiodarone.23 MDEA is known to exert toxic effects at
lower concentrations than amiodarone.42,43 In line with
these observations, 10 mol/L MDEA, but not amiod-
arone, was toxic for endothelial cells. At lower concentra-
tions, MDEA impaired TF expression and may thus
potentiate the antithrombotic effect of amiodarone. MDEA
and amiodarone seem to be degraded further, because
elevated excretion of free iodine has been observed in
humans treated with amiodarone.44 The free iodine is
mainly responsible for changes in thyroid function result-
ing in hypo- or hyperthyroidism;45,46 nevertheless, the
iodine is not essential for inhibition of TF protein expres-
sion, because amiodarone lacking iodine suppressed TF
expression to a similar extent as amiodarone.
About 75% of all SCD are imputable to coronary artery
disease.3–5 The majority of them are triggered by ventric-
ular arrhythmia, often caused by acute coronary events.3
This is supported by evidence from autopsies, showing that
the majority of SCD are associated to acute coronary
thrombosis.6 – 8 Therefore, in patients with coronary artery
disease, it seems likely that acute thrombus formation is
the main initial event leading to SCD. In patients suffering
from myocardial infarction or congestive heart failure,
amiodarone reduced SCD by 29% and total mortality by
13%.20 The present study suggests that amiodarone may
decrease SCD not only by preventing ventricular arrhyth-
mia, but also by inhibiting arterial thrombosis. Indeed,
subgroup analysis of prophylactic amiodarone treatment
did not reveal a greater effectiveness in patients with
higher frequencies of ventricular arrhythmia,20 which sup-
ports the observation of a antithrombotic pleiotropic effect
of amiodarone contributing to the reduction of SCD.
In summary, the present study demonstrates that amiod-
arone, at clinically relevant concentrations, inhibits arterial
2236 Arterioscler Thromb Vasc Biol December 2008
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thrombus formation by decreasing TF activity and platelet
number in a mouse thrombosis model in vivo. A conserved
effect was observed in human vascular cells where amiod-
arone inhibited TF activity and protein expression at the
translational level. Because thrombosis is the main initial
event leading to SCD in patients with coronary artery disease,
these results reveal new possible insights with respect to the
beneficial actions of amiodarone.
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Material and Methods 
 
Carotid artery thrombosis model 
14 week old C57BL/6 mice weighing on average 28g were anesthetized by 
intraperitoneal injection of 87 mg/kg sodium pentobarbital (Butler, Columbus, OH). 
Rose bengal (Fisher Scientific, Fair Lawn, NJ) was diluted to 12 mg/mL in phosphate-
buffered saline and then injected into the tail vein at a concentration of 63 mg/kg. 
Mice were secured in a supine position, placed under a dissecting microscope, and 
the right common carotid artery was exposed following a midline cervical incision. A 
Doppler flow probe (Model 0.5 VB, Transonic Systems, Ithaca, NY) was applied and 
connected to a flowmeter (Transonic, Model T106). 6 minutes after rose bengal 
injection, a 1.5-mW green light laser (540 nm; Melles Griot, Carlsbad, CA) was 
applied to the site of injury at a distance of 6 cm for 60 minutes or until thrombosis 
occurred. From the onset of injury, blood flow was monitored up to 120 minutes, at 
which time the experiment was terminated21. Occlusion was defined as flow ≤0.1 
ml/min for at least 1 minute. Mice were divided into 2 groups: Amiodarone (80 mg/kg 
with an intraperitoneal injection every 24 hours for 7 days), or vehicle control (1.43% 
Tween 80, 0.29% benzyl alcohol) 
 
Amiodarone and MDEA concentration in mouse plasma and thoracic aorta 
 Concentrations of amiodarone and MDEA in mouse plasma and thoracic aorta 
were measured by high performance liquid chromatography [HPLC; LiChrospher®60, 
5C18; 250 x i.d. 4mm; mobile phase: methanol:water:25% NH3 (89.47:8.77:1.76w/w); 
flow rate: 1ml/min]. Aorta (25 mg) was homogenized in 0.5 ml methanol at 4°C using 
a Potter S glass homogenizer (Braun, Melsungen, Germany). After centrifugation at 
3000g, the pellet was washed twice with 0.25 ml methanol. The organic extracts were 
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pooled and evaporated to dryness (Speed Vac, Savant Instruments Inc., 
Farmingdale, NY). To the residue was dissolved in 75µl of the mobile, and an aliquot 
of 50 µl was analyzed. Plasma (200 µl) was mixed with 0.1 ml 0.5 mM KH2PO4 and 
extracted three times with 0.75 ml diethylether. The organic extracts were pooled and 
evaporated to dryness as described. The residue was dissolved in 100 µl of 
methanol, and an aliquot of 50 µl was used for HPLC. 
 
PTT, aPTT, tail bleeding time, and blood cell counts  
 Prothrombin time (PTT) and activated partial thromboplastin time (aPTT) were 
assessed by the Start4 analyzer (Diagnostica Stago, France) with according reagents 
(Roche Diagnostics, Switzerland). Plasma from citrated blood (3.2% citrate 1/10) was 
extracted by 15 minutes centrifugation (2500g, 4°C), and stored immediately at -80°C 
until analysis. Tail bleeding time was assessed as described23. Briefly, after 
anesthetizing mice, the distal 4-mm segment of the tail was removed with a scalpel. 
Bleeding was monitored by gently absorbing the blood with a filter paper at 15 
second intervals without touching the wound. To count blood cells, whole blood was 
collected in heparin-coated tubes and analyzed by flow cytometry. 
 
Cell Culture  
Human aortic endothelial cells (HAECs; Clonetics, Allschwil, Switzerland) and 
human aortic vascular smooth muscle cells (HAVSMCs; Clonetics) were cultured as 
described22. Adhering HAECs were grown to confluence and rendered quiescent for 
24 hours in medium containing 0.5% FCS before stimulation, whereas HAVSMCs 
were kept in medium containing 0.2% BSA for 48 hours. Cells were pretreated with 
amiodarone (Sigma, Buchs, Switzerland), N-monodesethylamiodarone (MDEA), or 
amiodarone lacking iodine (AMWI). The amiodarone derivatives were prepared by 
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condensing [2-butyl-3-(3.5-diiodo-4-hydroxybenzoyl)-benzofuran] and [2-butyl-3-(4-
hydroxybenzoyl)-benzofuran] with 2-chloroethylamine as previously described24. 
Their chemical structures were confirmed by 1H-NMR, ESI-MS analysis. Cells were 
stimulated with 5 or 10 ng/ml tumor necrosis factor alpha (TNF-α; R&D Systems, 
Minneapolis, MN) or 1 U/ml thrombin (R&D Systems), respectively. Cytotoxicity was 
assessed by a colorimetric assay to detect lactate dehydrogenase (LDH; Roche, 
Basel, Switzerland). 
 
Western Blot Analysis 
Protein expression was determined by western blot analysis. Antibodies 
against human TF and tissue factor pathway inhibitor (TFPI; both from American 
Diagnostica, Stamford, CT) were used at 1:2000 dilution. Antibodies against 
phosphorylated p38 MAP kinase (p38), p44/42 MAP kinase (ERK), and c-Jun NH2-
terminal kinase (JNK; all from Cell Signaling, Danvers, MA) were used at 1:1000, 
1:5000, and 1:1000 dilution, respectively. Antibodies against total p38, ERK, and JNK 
(all from Cell Signaling) were diluted to 1:3000, 1:2000, and 1:1000, respectively. The 
antibody against IkB-α (Santa Cruz Biotechnology, Santa Cruz, CA) was applied at a 
1:1000 dilution. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Chemicon, 
Temecula, CA) or alpha-tubulin (aT; Sigma) were applied to control for equal protein 
loading (1:10000 dilution). Primary antibodies were detected with a horseradish 
peroxidase-linked secondary antibody (Amersham, Munich, Germany).  
 
Real-time PCR 
 Total RNA was extracted from HAECs with 1 mL TRIzol Reagent (Invitrogen, 
Lucerne, Switzerland) as described12. Conversion of total cellular RNA to cDNA was 
carried out with Moloney murine leukemia virus reverse transcriptase and random 
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hexamer primers (Amersham) in a final volume of 33 µL using 4 µg of RNA. The total 
cDNA pool obtained served as template for subsequent PCR amplification with 
primers specific for full-length TF (sense primer: 5’-
TCCCCAGAGTTCACACCTTACC–3’, antisense primer: 5’-
CCTTTCTCCTGGCCCATACAC–3’; bases 508-529 of F3 cDNA; NCBI no. NM 
001993). Real-time PCR amplification was performed in a MX3000P PCR cycler 
(Stratagene) using the SYBR Green JumpStart kit (Sigma) in 25 µL final reaction 
volume containing 2 µL cDNA, 10 pmol of each primer, 0.25 µL of internal reference 
dye, and 12.5 µL of JumpStart Taq ReadyMix (buffer, dNTP, stabilizers, SYBR 
Green, Taq polymerase, and JumpStart Taq antibody)25. A melting curve analysis 
was performed after amplification to verify the accuracy of the amplicon. L28 RNA 
served as loading control.  
 
TF activity 
TF surface activity in HAECs and TF activity in mouse carotid artery tissue 
homogenates was analyzed using a colorimetric assay (American Diagnostica)21. 
Cells were incubated at 37°C with human FVIIa and FX, allowing for the formation of 
TF/FVIIa complex at the cell surface. Left carotid arteries from amiodarone treated 
mice were homogenized in 50 µl lysis buffer (50 mmol Tris-HCl, 100 mmol NaCl, 
0.1% Triton X-100 pH 7.4) before incubation. Conversion of FX to FXa was 
measured by the ability of FXa to cleave a chromogenic substrate. A standard curve 
was established with lipidated human TF to assure that the results were in the linear 
range of detection. 
 
Metabolic labeling  
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HAECs were starved, either with or without amiodarone (10 µmol/l) pre-
treatment, in FCS-free Dulbecco’s modified Eagle medium (DMEM) lacking 
methionine and cysteine. After 1 hour, cells were kept in the same medium 
supplemented with [35S]-methionine/cysteine (100 µCi/ml; Hartmann Analytics, 
Braunschweig, Germany) and stimulated with TNF-α (5 ng/ml) for 5 hours. TF was 
immunoprecipitated from cell lysates (150 µl) using a goat anti-human TF antibody (1 
µg; R&D Systems) or nonimmune goat IgG (1 µg; Sigma) for 3 hours at 4°C, followed 
by incubation with protein G sepharose beads (Sigma) for 1 hour under the same 
conditions. Antibody-protein complexes were washed five times and separated on a 
10% SDS-Page. Labelled TF was visualized by Molecular Imager FX (Bio-Rad, 
Hercules, CA). 
 
Intracellular potassium concentration 
HAECs were supplemented with 86Rb (0.5 µCi/ml) and incubated at 37ºC for 4 
hours. Ouabain (1 µmol/L), as a positive control, or amiodarone (10 µmol/L) were 
added to the cells together with the radioactive tracer. After washing, cells were lysed 
and the amount of intracellular 86Rb was measured using a Packard Tri-Carb 1600 
TR liquid scintillation counter (Packard, Meriden, CT). Data were plotted against the 
incubation time, and the plots fitted as an exponential function y = yo + a•exp(-bx) 
using the SigmaPlot analysis module. Uptake of the radioactive tracer was 
normalized to the amount of protein in cell lysate and related to the radioactivity of 
the incubation medium.  
 
Statistical Analysis 
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 Data are indicated as mean ± SEM. Unpaired Student’s t-test was performed 
for statistical analysis. A p value <0.05 denoted a significant difference. 
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Table I 
 
Effect of amiodarone on PTT, aPTT, platelet number, and tail bleeding time. 
 Control (n=7) Amiodarone (n=7) 
PTT [seconds] 11.50±0.11 11.19±0.15 
aPTT [seconds] 20.24±0.79 20.70±0.83 
Total platelet number [x103/µl] 1056±22 789±42* 
Tail bleeding time [seconds] 393.0±145.0 349.3±92.3 
*P<0.05 
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